J
Jaume Reventós
Researcher at International University Of Catalonia
Publications - 114
Citations - 7992
Jaume Reventós is an academic researcher from International University Of Catalonia. The author has contributed to research in topics: Endometrial cancer & Cancer. The author has an hindex of 39, co-authored 111 publications receiving 6408 citations. Previous affiliations of Jaume Reventós include Autonomous University of Barcelona & University of Lleida.
Papers
More filters
Journal ArticleDOI
Sertoli cell-specific expression of rat androgen-binding protein in transgenic mice: effects on somatic cell lineages.
TL;DR: The morphological modifications present in Leydig, Sertoli, and peritubular cells of the testis of young adult male mice transgenic for ABP gene, which overproduce ABP in testis are analyzed.
Journal ArticleDOI
A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry
Maria Santacana,Oscar Maiques,Joan Valls,Sonia Gatius,Ana Isabel Abó,María Ángeles López-García,Alba Mota,Jaume Reventós,Gema Moreno-Bueno,José Palacios,Carla Bartosch,Xavier Dolcet,Xavier Matias-Guiu +12 more
TL;DR: An internally and externally validated 9-protein biomarker signature is proposed to predict the histologic type of EC (EEC or SC) by IHC and suggests that mixed EEC-SC is molecularly ambiguous.
Journal ArticleDOI
Advances in endometrial cancer protein biomarkers for use in the clinic.
Elena Martinez-Garcia,Carlos Lopez-Gil,Irene Campoy,Julia Vallve,Eva Coll,Silvia Cabrera,Santiago Ramón y Cajal,Xavier Matias-Guiu,Jan van Oostrum,Jaume Reventós,Antonio Gil-Moreno,Eva Colas +11 more
TL;DR: New perspectives in EC biomarker research are addressed, including the comprehensive knowledge of previously suggested candidate biomarkers in conjunction with novel mass spectrometry-based proteomic technologies with enhanced sensitivity and specificity not yet applied to EC studies and a directed clinical perspective in the study design.
Journal ArticleDOI
Apoptosis in epithelial ovarian tumours: Prognostic significance of clinical and histopathologic factors and its association with the immunohistochemical expression of apoptotic regulatory proteins (p53, bcl-2 and bax)
F Javier de la Torre,Ángel García,Antonio Gil-Moreno,Jesús Planagumà,Jaume Reventós,Santiago Ramón y Cajal,Jordi Xercavins +6 more
TL;DR: The results indicate that the apoptotic index and p53 nuclear accumulation are independent predictive factors of recurrence and short survival and different patterns of alterations for the various tumour types are suggested.
Journal ArticleDOI
Cyclooxygenase‐2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice
Marta Garcia,Marta Garcia,Roberto Vélez,Roberto Vélez,Cleofé Romagosa,Cleofé Romagosa,Blanca Majem,Blanca Majem,Nuria Pedrola,Nuria Pedrola,Mireia Olivan,Marina Rigau,Marina Rigau,Marc Guiu,Roger R. Gomis,Juan Morote,Juan Morote,Jaume Reventós,Jaume Reventós,Jaume Reventós,Andreas Doll,Andreas Doll +21 more
TL;DR: To assess whether celecoxib, a selective cyclooxygenase‐2 (COX‐2) inhibitor with anti‐cancer properties, has an inhibitory effect on tumour establishment and progression of prostate cancer (PCa) bone metastases, a large number of animals were vaccinated against PCa.